-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

Benzinga·08/17/2026 13:57:47
Listen to the news
Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.